Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

Who May Qualify: 1. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year); 2. Age from 18 to 65 years old; 3. Clinical diagnosis of liver failure (serum total bilirubin level \> 10 times upper limit of normal; prothrombin time activity \< 40% and ≥20%, or prothrombin time international ratio ≤ 2.6 and \> 1.5); 4. Platelets \> 50\*10 E9/L. Who Should NOT Join This Trial: 1. Other active liver diseases; 2. Hepatocellular carcinoma or other malignancy; 3. Pregnancy or lactation; 4. Human weakened immune system virus infection or congenital immune deficiency diseases; 5. Severe diabetes, autoimmune conditions (where your immune system attacks your own body)s; unstable infarction due to cardio-cerebrovascular events; 6. Other important organ dysfunctions or transplantation; 7. Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome; 8. Patients can not follow-up; 9. Investigator considering inappropriate. Always talk to your doctor about whether this trial is right for you.